Boule Diagnostics AB Publ Reports Earnings Results for the Third Quarter Ended September 30, 2020
November 05, 2020 at 09:00 am
Share
Boule Diagnostics AB publ announced earnings results for the third quarter ended September 30, 2020. For the third quarter, the company announced sales was SEK 98.8 million compared to SEK 131.2 million a year ago. Operating income was SEK 23.5 million compared to SEK 32.3 million a year ago. Net income was SEK 20.2 million compared to SEK 20.3 million a year ago. Basic earnings per share from continuing operations was SEK 1.04 compared to SEK 1.04 a year ago. For the nine months, sales was SEK 307.8 million compared to SEK 369.6 million a year ago. Operating income was SEK 35.7 million compared to SEK 54.9 million a year ago. Net loss was SEK 15.4 million compared to net income of SEK 30.4 million a year ago. Basic loss per share from continuing operations was SEK 0.79 compared to basic earnings per share from continuing operations of SEK 1.56 a year ago.
Boule Diagnostics AB is a Sweden-based company engaged in the provision of medical diagnostic and testing equipment. The Company specializes in the development, manufacture and sale of complete blood count (CBC) systems in the field of hematology. It provides reagents, cleaning products and blood calibrators and controls that are used in human and veterinarian laboratories, as well as analyzers and complementing accessories for hematology systems. The Companyâs product portfolio comprises five brands: Clinical Diagnostic Solutions, Exigo, Medonic, Swelab and Quintus. The Companyâs primary customer base comprises small and medium-sized hospitals, clinics, diagnostics firms and laboratories. Furthermore, It operates worldwide through a number of subsidiaries, such as Boule Medical AB, Boule Nordic AB, Clinical Diagnostic Solutions Inc and Boule Medical (Beijing) Co Ltd.
BOULE DIAGNOSTICS AB 
